Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Incyte reported $1.18 billion in revenue for Q4 2024, a 16.3% year-over-year increase, with an EPS of $1.43 compared to $1.06 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $1.15 billion by 2.63%, while the EPS fell short of the consensus estimate of $1.53 by 6.54% [1] Revenue Breakdown - Product royalty revenues were $159.29 million, slightly below the average estimate of $161.69 million, reflecting a 6.5% year-over-year increase [4] - Net product revenues for Iclusig were $27.37 million, compared to the average estimate of $29.69 million, marking a 0.9% year-over-year change [4] - Net product revenues for Pemazyre reached $23.14 million, exceeding the average estimate of $19.08 million, with a year-over-year increase of 12.1% [4] - Net product revenues for Minjuvi/Monjuvi were $32.81 million, slightly below the estimate of $33.75 million, but showed a significant year-over-year increase of 264.8% [4] - Net product revenues for Opzelura were $161.60 million, surpassing the average estimate of $150.33 million, with a year-over-year increase of 47.9% [4] - Net product revenues for Jakafi were $773.11 million, exceeding the average estimate of $745.88 million, reflecting an 11.2% year-over-year increase [4] - Net product revenues for Zynyz were $1.37 million, above the average estimate of $0.96 million [4] - Total product revenues amounted to $1.02 billion, exceeding the average estimate of $999.96 million, with an 18.3% year-over-year increase [4] - Royalty revenues for Olumiant were $38.49 million, slightly below the estimate of $39.58 million, showing a 4.6% year-over-year decrease [4] - Royalty revenues for Tabrecta were $6.29 million, in line with the average estimate of $6.27 million, reflecting a 34.4% year-over-year increase [4] - Royalty revenues for Jakavi were $114.19 million, slightly below the estimate of $116.30 million, with a 9.9% year-over-year increase [4] - Royalty revenues for Pemazyre were $0.33 million, below the average estimate of $0.67 million [4] Stock Performance - Incyte's shares have returned +5.1% over the past month, outperforming the Zacks S&P 500 composite's +2.1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]